DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma

Figure 7

FGFR1 knockdown impairs tumor growth and angiogenesis of sorafenib-resistant HCC cells in vivo. (a and b) Pilot studies of tumor xenograft experiments were performed for HUH-7/R cells with 3 groups of treatment: i.e., vehicle control; sorafenib+DJ-1; and sorafenib+DJ-1+shFGFR1. cells per injection were injected subcutaneously into two flanks of nude mice (), and tumor weight (a) and tumor volume (b) were recorded. Tumor volume was checked twice to three times weekly using a digital caliper. (c and d) Tumor cell angiogenesis was examined in the chicken chorioallantoic membrane (CAM) model. Both HUH-7 and HUH-7/R cells were mixed with ECDHCC-1 cells at the ratio of 1 : 1 and then treated at different conditions: (1) cells+control; (2) cells+DJ-1; (3) cells+corafenib; (4) cells+sorafenib+DJ-1; and (5) cells+sorafenib+DJ-1+shFGFR1. In CAM model, total vessel length (c) and density (d) were measured at the end of the experiments.

(a)

(b)

(c)

(d)